Literature DB >> 3980657

Reversed-phase high-performance liquid chromatographic determination of tricyclic nucleoside and tricyclic nucleoside 5'-phosphate in biological specimens.

R B Schilcher, J D Young, L H Baker.   

Abstract

An isocratic, sensitive, high-performance liquid chromatographic assay was developed for the determination of the tricyclic nucleoside 1,4,5,6,8-pentaazaacenaphthylene -3-amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl 5'-monophosphate (TCN-P; NSC 280594) and its dephosphorylated metabolite TCN (NSC 154020). Separation was obtained using a C18 Sep-Pak precolumn, a reversed-phase column, and a mobile phase of phosphate buffer--methanol (87.5:12.5, v/v) containing 0.0025 M tetrabutylammonium hydroxide. The absorbance of both TCN and TCN-P was monitored at 280 nm with a sensitivity limit of 10 ng/ml. The recovery was 54 +/- 6% and 51 +/- 8% (mean +/- S.D.) from plasma for TCN and TCN-P, respectively. Rapid enzymatic dephosphorylation of TCN-P in plasma and tissue samples was prevented by adding a large excess of adenosine 5'-monophosphate. The assay was used to determine plasma and tissue concentrations of TCN-P and TCN after administration of TCN-P to cancer patients in a Phase I clinical study.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3980657     DOI: 10.1016/0378-4347(85)80007-4

Source DB:  PubMed          Journal:  J Chromatogr


  3 in total

1.  Phase I-II study: triciribine (tricyclic nucleoside phosphate) for metastatic breast cancer.

Authors:  K Hoffman; F A Holmes; G Fraschini; L Esparza; D Frye; M N Raber; R A Newman; G N Hortobagyi
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

2.  A rational approach to personalized anticancer therapy: chemoinformatic analysis reveals mechanistic gene-drug associations.

Authors:  Kerby Shedden; Leroy B Townsend; John C Drach; Gustavo R Rosania
Journal:  Pharm Res       Date:  2003-06       Impact factor: 4.200

3.  Proteome activity landscapes of tumor cell lines determine drug responses.

Authors:  Martin Frejno; Chen Meng; Benjamin Ruprecht; Thomas Oellerich; Sebastian Scheich; Karin Kleigrewe; Enken Drecoll; Patroklos Samaras; Alexander Hogrebe; Dominic Helm; Julia Mergner; Jana Zecha; Stephanie Heinzlmeir; Mathias Wilhelm; Julia Dorn; Hans-Michael Kvasnicka; Hubert Serve; Wilko Weichert; Bernhard Kuster
Journal:  Nat Commun       Date:  2020-07-20       Impact factor: 14.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.